FY2027 EPS Estimate for Kodiak Sciences Lowered by Analyst

Kodiak Sciences Inc. (NASDAQ:KOD) – HC Wainwright decreased their FY2027 earnings estimates for Kodiak Sciences in a research note issued to investors on Monday, September 28th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($3.36) per share for the year, down from their previous forecast of ($3.27). HC Wainwright has a “Buy” rating and a $96.00 price target on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.89) per share. HC Wainwright also issued estimates for Kodiak Sciences’ FY2028 earnings at ($1.78) EPS, FY2029 earnings at $1.76 EPS and FY2030 earnings at $5.81 EPS.

Kodiak Sciences (NASDAQ:KOD) last released its earnings results on Thursday, August 13th. The company reported ($1.05) EPS for the quarter, missing analysts’ consensus estimates of ($0.96) by ($0.09).

Other equities research analysts have also recently issued reports about the company. Lifesci Capital lifted their price objective on Kodiak Sciences from $85.00 to $145.00 and gave the stock an “outperform” rating in a research note on Monday. Jefferies Financial Group restated a “buy” rating and set a $112.00 target price on shares of Kodiak Sciences in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Kodiak Sciences in a report on Friday, July 10th. Wall Street Zen lowered Kodiak Sciences from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, JPMorgan Chase & Co. upped their price target on Kodiak Sciences from $56.00 to $66.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $100.43.

Kodiak Sciences Stock Up 1.3%

NASDAQ:KOD opened at $91.12 on Wednesday. Kodiak Sciences has a 12-month low of $10.94 and a 12-month high of $95.77. The firm has a market capitalization of $5.73 billion, a P/E ratio of -21.75 and a beta of 2.18. The stock’s fifty day simple moving average is $40.26 and its 200-day simple moving average is $38.27.

Institutional Trading of Kodiak Sciences

Several hedge funds have recently added to or reduced their stakes in the business. Engineers Gate Manager LP raised its position in shares of Kodiak Sciences by 145.8% during the second quarter. Engineers Gate Manager LP now owns 29,537 shares of the company’s stock worth $1,151,000 after purchasing an additional 17,520 shares during the period. Squarepoint Ops LLC grew its position in shares of Kodiak Sciences by 112.6% in the 2nd quarter. Squarepoint Ops LLC now owns 151,098 shares of the company’s stock valued at $5,887,000 after purchasing an additional 80,042 shares during the period. Arizona State Retirement System grew its position in shares of Kodiak Sciences by 6.9% in the 2nd quarter. Arizona State Retirement System now owns 8,533 shares of the company’s stock valued at $332,000 after purchasing an additional 554 shares during the period. Hsbc Holdings PLC bought a new stake in Kodiak Sciences during the 2nd quarter worth approximately $232,000. Finally, Wellington Management Group LLP increased its stake in Kodiak Sciences by 81.9% during the 2nd quarter. Wellington Management Group LLP now owns 793,613 shares of the company’s stock worth $30,919,000 after purchasing an additional 357,284 shares in the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Key Kodiak Sciences News

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Phase 3 success supports potential approval: Zenkuda and tabirafusp-ted (KSI-501) met their primary endpoints in the DAYBREAK study, with results indicating efficacy comparable to Regeneron’s established Eylea. Kodiak plans to advance Zenkuda toward a biologics license application (BLA), moving the drug closer to commercialization. KOD Stock Soars on Positive Wet AMD Data
• Positive Sentiment: Analysts raised price targets: Lifesci Capital increased its target from $85 to $145 and retained an outperform rating. UBS raised its target from $80 to $120 with a buy rating, while HC Wainwright lifted its target from $58 to $96 and also maintained a buy rating. The revisions reflect greater confidence in Kodiak’s regulatory and commercial prospects. Lifesci Capital Raises Price Target
• Positive Sentiment: Large addressable market: Coverage highlighted the potential opportunity in retinal drugs, a market expected to exceed $32 billion by the end of the decade. A longer-acting treatment that can compete with Eylea could offer meaningful commercial upside if approved. Why Kodiak Sciences Skyrocketed

Kodiak Sciences Company Profile

Kodiak Sciences Inc (NASDAQ: KOD) is a biopharmaceutical company focused on developing therapies for retinal diseases and other conditions affecting the eye. The company’s research is centered on antibody biopolymer conjugates, a technology designed to extend the duration of action of biologic medicines in ocular tissues and potentially reduce the frequency of administration.

Its lead development program has been tarcocimab tedromer, also known as KSI-301, an anti-vascular endothelial growth factor (VEGF) therapy investigated for retinal vascular diseases, including diabetic macular edema, diabetic retinopathy and neovascular age-related macular degeneration.